- Large cohort study found no increased risk of suicidality in type 2 diabetes patients with GLP-1 receptor agonists.
- Initial crude analyses suggested increased incidence of suicidality with GLP-1 receptor agonists, but the association was null after adjusting for confounders.
- Similar pattern was observed when comparing GLP-1 receptor agonists with SGLT-2 inhibitors.
- GLP-1 receptor agonists do not seem to increase the risk of suicidality among patients with type 2 diabetes.
- Clinical trials have not shown imbalances in suicidal ideation or self-harm between treatment groups.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
